The Patient Participated In The Phase Ii Liver Cancer Study And Has Been Treated With Namodenoson For >7 Years Under Compassionate Use Program
Can-Fite Biopharma Announced It Published An Article In The Experimental And Therapeutic Medicine Journal, "Long-term Complete Response To Namodenoson In Liver Cancer With Child-Pugh B Cirrhosis
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.